Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Dissection of subclonal evolution by temporal mutation profiling in chronic lymphocytic leukemia patients treated with ibrutinib

10 Jun 2019

Abstract excerpt

The Bruton's tyrosine kinase (BTK) inhibitor ibrutinib is inducing durable responses in chronic lymphocytic leukemia (CLL) patients with refractory/relapsed disease or with TP53 defect, with BTK and phospholipase C gamma 2 (PLCG2) mutations representing the predominant mechanisms conferring secondary ibrutinib resistance. To understand the landscape of genomic changes and the dynamics of subclonal architecture...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chronic Lymphocytic Leukemia Research
Share to Immunodeficiency and Autoimmune Disorders
Share to PI3K/AKT/mTOR signaling in cancer

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 31180577
DOI: 10.1002/ijc.32502

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Dissection of subclonal evolution by temporal mutation profiling in chronic lymphocytic leukemia patients treated with ibrutinibPMID 31180577Read ↗

BTK and PLCG2 remain unmutated in one-third of patients with CLL relapsing on ibrutinibSemantic proximity Read ↗

Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition.Semantic proximity Read ↗

Genomic evolution of ibrutinib‐resistant clones in Waldenström macroglobulinaemiaSemantic proximity Read ↗

Early reappearance of intraclonal proliferative subpopulations in ibrutinib-resistant chronic lymphocytic leukemia.Semantic proximity Read ↗

Longitudinal CITE-Seq profiling of chronic lymphocytic leukemia during ibrutinib treatment: evolution of leukemic and immune cells at relapseSemantic proximity Read ↗

The evolutionary landscape of chronic lymphocytic leukemia treated with ibrutinib targeted therapy.Semantic proximity Read ↗

Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma.Semantic proximity Read ↗

Ultra-deep mutational landscape in chronic lymphocytic leukemia uncovers dynamics of resistance to targeted therapies.Semantic proximity Read ↗

Therapy-driven clonal dynamics in chronic lymphocytic leukemia.Semantic proximity Read ↗

Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemiaSemantic proximity Read ↗

Predictive significance of selected gene mutations in relapsed and refractory chronic lymphocytic leukemia patients treated with ibrutinib.Semantic proximity Read ↗

Mutations Detected in Real World Clinical Sequencing during BTK Inhibitor Treatment in CLLSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.